πŸ‡ΊπŸ‡Έ FDA
Patent

US 11299553

Anti-plasma kallikrein antibodies

granted A61PA61P29/00A61P31/04

Quick answer

US patent 11299553 (Anti-plasma kallikrein antibodies) held by Takeda Pharmaceutical Company Limited expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P29/00, A61P31/04, A61P35/00, A61P43/00